Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA guidance development will "in general" provide for public input, Schultz says.

This article was originally published in The Gray Sheet

Executive Summary

FDA GUIDANCE DEVELOPMENT POLICY WILL "IN GENERAL" PROVIDE FOR PUBLIC COMMENT, as well as an appeals process for manufacturers objecting to a guidance, FDA Deputy Commissioner for Policy William Schultz said Sept. 14 at a House Government Reform Committee hearing. The policy will be released in October, Schultz told the hearing, which was held jointly by Rep. Christopher Shays' (R-Conn.) Human Resources Subcommittee and Rep. David McIntosh's (R-Ind.) National Economic Growth Subcommittee.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT004704

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel